Michelson Diagnostics' VivoSight OCT Scanner used to Evaluate Microneedle Drug Delivery System

(Orpington, UK) September 30, 2010 -- Michelson Diagnostics (MDL) the leading provider of clinical OCT imaging systems is pleased to report the use of its VivoSight OCT imaging system to evaluate the performance of a new microneedle drug delivery technology by researchers at Queen's University Belfast led by Dr Ryan Donnelly. The research, to be published in the Journal of Controlled Release*1 (Elsevier), shows how the VivoSight system was used to directly image the microneedles penetrating the skin, and how the results were used to evaluate the effects of microneedle spacing and force of application.

Drug delivery systems using microneedle arrays are of great interest to pharmaceutical companies who would like to alleviate the discomfort of the standard hypodermic needle with an easy to administer, painless drug delivery method. Many companies are developing microneedle technology, targeting a slice of the $18bn drug delivery device market.  The microneedles range from hollow or coated steel arrays to biodegradable polymer needles that dissolve once injected.

Microneedle developers aim to design devices that are effective at penetrating the surface layer of skin, known as the stratum corneum, to deliver drugs to the dermis, whilst being short and narrow enough to avoid stimulating the dermal nerves and causing discomfort. It is important to understand how a change in microneedle design and application method affects the device performance.

According to the authors of the paper, "The successful use of OCT in this study could prove to be a key development for polymeric micro-needle research, accelerating their commercial exploitation." "The VivoSight system is a unique tool for transdermal drug delivery development. It is the only clinical technology that can image the needles in situ, in real time," said Dr Daniel Woods, Senior Imaging Scientist at Michelson Diagnostics Ltd., adding "The high resolution and extended penetration depth of VivoSight mean that researchers can really understand how the needles interact with the skin."

About Michelson Diagnostics

Michelson Diagnostics was founded in 2006; it is privately owned and based in Kent, U.K. The company develops imaging products using a technology called Multi-Beam Optical Coherence Tomography. The technology provides real time images of up to 2mm into tissue with a resolution of better than 10 microns. The company's products include the EX1301 OCT Microscope which is used by researchers in a variety of fields including dermatology, developmental biology and industrial metrology; and the VivoSight OCT scanner which has CE and 510(k) clearance for use to aid clinical judgments in the field of dermatology. Applications of VivoSight include non-melanoma skin cancer screening and guiding skin cancer surgery.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.